Imperative Care Inc.11.22.21
Imperative Care Inc. has appointed three members to its Board of Directors: Holly Sheffield, Hank Plain, and James Rogers.
“We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts,” said Fred Khosravi, chairman and CEO of Imperative Care. “Having these professionals join our Board speaks to the potential of our programs in bringing more innovative technologies to market faster and meeting patients’ needs in the fields of stroke and peripheral vascular disease.”
After a career of more than 20 years in investment banking, Sheffield joined CooperCompanies as executive vice president, chief strategy officer in June 2018. Last year, Sheffield was named president of CooperSurgical, one of Cooper Companies’ two business units. CooperSurgical is focused on advancing the standard of healthcare for women and families worldwide. Prior to this, she was managing director and global head of Medical Technology Investment Banking at UBS Securities. She also worked at Donaldson, Lufkin & Jenrette, where she started in 1997, until its acquisition by Credit Suisse, where she stayed as a managing director until 2009. Sheffield graduated from Cornell University and obtained her MBA from Columbia University.
Before transitioning to the world of venture capital, Plain began his career in the pharmaceutical and medical device industries more than 40 years ago. As the CEO of Perclose, he led the company through a successful IPO and acquisition by Abbott Laboratories. Following this, he co-founded eight medical device companies as part of his work at The Foundry medical device incubator. In addition to currently serving as Partner of Morgenthaler Ventures and Lightstone Ventures, he is on numerous boards, including Nuvaira, Moximed, Earlens, and Setpoint. Plain also serves as board chairman for the Naval Postgraduate School Foundation and is a board member of the Future Citizens Foundation/First Tee. Plain graduated from the University of Missouri with a bachelor of science degree in finance.
Rogers is an analyst at D1 Capital Partners, the lead investor in Imperative Care’s $260 million Series D financing announced over the summer. Since D1 launched in July 2018, Rogers has led more than a dozen private financings, including investments in medical technology companies such as Auris Health, Outset Medical, and Sight Sciences. Previously, he was a principal at Valinor Management and an analyst at The Blackstone Group. Rogers graduated from the University of Virginia with a bachelor of science degree in commerce and a bachelor of arts degree in history as a Jefferson Scholar and an Echols Scholar.
“Imperative Care’s intentional mission to impact the continuum of stroke care and vascular thrombectomy, elevating innovations in order to make more care available to more patients globally, requires a board with a long-term horizon and broad expertise. Holly, Hank, and James will further strengthen the prowess of the existing Imperative Care board, to help achieve this important mission. We are delighted to have them on the team,” said John Hamre, Ph.D., chairman of the Nominating and Governance Committee of the Imperative Care’s Board of Directors.
Imperative Care is a vascular technology company focused on developing the next generation of innovative solutions to address the vast and urgent needs in stroke. The company has two U.S. Food and Drug Administration 510(k)-cleared product platforms, as well as an expansive stroke technology development pipeline. In addition, Imperative Care’s wholly owned subsidiary, Truvic Medical Inc., is developing solutions for the treatment of peripheral vascular disease. Imperative Care and Truvic Medical are based in Campbell, Calif.
“We are grateful to have the guidance of Holly, Hank, and James as they bring distinctive and complementary industry leadership to Imperative Care as we continue to accelerate our development and commercialization efforts,” said Fred Khosravi, chairman and CEO of Imperative Care. “Having these professionals join our Board speaks to the potential of our programs in bringing more innovative technologies to market faster and meeting patients’ needs in the fields of stroke and peripheral vascular disease.”
After a career of more than 20 years in investment banking, Sheffield joined CooperCompanies as executive vice president, chief strategy officer in June 2018. Last year, Sheffield was named president of CooperSurgical, one of Cooper Companies’ two business units. CooperSurgical is focused on advancing the standard of healthcare for women and families worldwide. Prior to this, she was managing director and global head of Medical Technology Investment Banking at UBS Securities. She also worked at Donaldson, Lufkin & Jenrette, where she started in 1997, until its acquisition by Credit Suisse, where she stayed as a managing director until 2009. Sheffield graduated from Cornell University and obtained her MBA from Columbia University.
Before transitioning to the world of venture capital, Plain began his career in the pharmaceutical and medical device industries more than 40 years ago. As the CEO of Perclose, he led the company through a successful IPO and acquisition by Abbott Laboratories. Following this, he co-founded eight medical device companies as part of his work at The Foundry medical device incubator. In addition to currently serving as Partner of Morgenthaler Ventures and Lightstone Ventures, he is on numerous boards, including Nuvaira, Moximed, Earlens, and Setpoint. Plain also serves as board chairman for the Naval Postgraduate School Foundation and is a board member of the Future Citizens Foundation/First Tee. Plain graduated from the University of Missouri with a bachelor of science degree in finance.
Rogers is an analyst at D1 Capital Partners, the lead investor in Imperative Care’s $260 million Series D financing announced over the summer. Since D1 launched in July 2018, Rogers has led more than a dozen private financings, including investments in medical technology companies such as Auris Health, Outset Medical, and Sight Sciences. Previously, he was a principal at Valinor Management and an analyst at The Blackstone Group. Rogers graduated from the University of Virginia with a bachelor of science degree in commerce and a bachelor of arts degree in history as a Jefferson Scholar and an Echols Scholar.
“Imperative Care’s intentional mission to impact the continuum of stroke care and vascular thrombectomy, elevating innovations in order to make more care available to more patients globally, requires a board with a long-term horizon and broad expertise. Holly, Hank, and James will further strengthen the prowess of the existing Imperative Care board, to help achieve this important mission. We are delighted to have them on the team,” said John Hamre, Ph.D., chairman of the Nominating and Governance Committee of the Imperative Care’s Board of Directors.
Imperative Care is a vascular technology company focused on developing the next generation of innovative solutions to address the vast and urgent needs in stroke. The company has two U.S. Food and Drug Administration 510(k)-cleared product platforms, as well as an expansive stroke technology development pipeline. In addition, Imperative Care’s wholly owned subsidiary, Truvic Medical Inc., is developing solutions for the treatment of peripheral vascular disease. Imperative Care and Truvic Medical are based in Campbell, Calif.